NeuroEndocrine Cancer Australia’s CEO recently participated in a panel discussion hosted by Boehringer Ingelheim focused on the importance of clinical trials, treatment access and improving outcomes for people living with neuroendocrine cancers.
The discussion included Dr Mike Akitov, Head of Global Clinical Development Oncology at Boehringer Ingelheim, during his visit from Switzerland, and brought together around 50 Boehringer Ingelheim staff to learn more about neuroendocrine cancers, the challenges faced by patients, and the work of NECA.
The session explored the role clinical trials can play for patients living with neuroendocrine cancers, including the impact of limited access to both trials and approved therapies. Discussions also highlighted the challenges patients can face when treatment options are limited, and the importance of continued collaboration across advocacy, clinical and industry sectors to improve access and outcomes.
An update was also provided on a clinical trial for patients with extra pulmonary neuroendocrine carcinomas (epNEC), with Australian investigators expected to begin participation in the coming months.
The discussion provided an important opportunity to increase awareness and understanding of neuroendocrine cancers within the pharmaceutical and research sector, while also exploring future opportunities for collaboration to help raise awareness of clinical trial opportunities for patients and healthcare professionals.
